AstraZeneca's Oncology Goal Separate Efficacy And Toxicity
Matthew Ellis, SVP of Early Oncology R&D for AstraZeneca, is helping lead the charge in what he calls the company's oncology revolution.
Source: clinicalleader.com
Stay updated with breaking news from Successful Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Matthew Ellis, SVP of Early Oncology R&D for AstraZeneca, is helping lead the charge in what he calls the company's oncology revolution.
Following are the latest Corporate Social Responsibility news releases and story ideas available from Business Wire. These recaps, curated by Business Wire, provide reporters and bloggers around the